YouTube Facebook LinkedIn Google+ Twitter Xingrss  

Firms Charge Fiduciary Breach in BGI-Complete Merger


By Bio-IT World Staff

September 18, 2012 | The announcement on Monday that Complete Genomics will be acquired by BGI for $117.6 million has left many surprised and dismayed. A slew of firms (nine at last count) starting with Rigrodsky & Long have announced investigations of the Complete Genomics Board of Directors. The investigations contend that the $3.15/share price may not be "fair" and are looking into breach of fiduciary duty on the part of the Board. Shareholders, including anonomyous blogger Medhanie at Seeking Alpha, are extremely unhappy with the decision. Medhanie calls the sell price "an insult". He continues: "I was proud of the company. By all accounts, it was a company on the vanguard of a biological and medical revolution and doing it despite surreal obstacles. It was a company to be admired. Now, it's giving up." The comments section is full of shareholders promising to vote no to the sale, but various investigation announcements yesterday point out that the proposed transaction is structured as a tender offer and may be effectuated without a shareholder vote.

View Next Related Story
Click here to login and leave a comment.  

1 Comments

  • Avatar

    Anonymous blogger Medhanie has never heard of BGI? Maybe he, she, or it has no business investing or blogging about an industry they know so little about.

Add Comment

Text Only 2000 character limit

Page 1 of 1


For reprints and/or copyright permission, please contact  Terry Manning, 781.972.1349 , tmanning@healthtech.com.